Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Accounts Payables (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Accounts Payables for 9 consecutive years, with $21.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 39.56% to $21.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.2 million, a 39.56% increase, with the full-year FY2025 number at $21.2 million, up 39.56% from a year prior.
  • Accounts Payables was $21.2 million for Q4 2025 at Akebia Therapeutics, up from $10.1 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $42.0 million in Q2 2021 to a low of $9.0 million in Q3 2023.
  • A 5-year average of $18.6 million and a median of $14.9 million in 2023 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: plummeted 54.14% in 2023, then surged 49.3% in 2024.
  • Akebia Therapeutics' Accounts Payables stood at $33.6 million in 2021, then tumbled by 46.35% to $18.0 million in 2022, then fell by 18.79% to $14.6 million in 2023, then rose by 3.72% to $15.2 million in 2024, then soared by 39.56% to $21.2 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Accounts Payables are $21.2 million (Q4 2025), $10.1 million (Q3 2025), and $11.6 million (Q2 2025).